2Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions:comparison by geographic region and with cervical cancer[J]. Cancer Epidemiol Biomarkers Prey, 2005, 14 (5) :1157-1164.
3Khan MJ,Castle PE,Lorincz AT,et al. The elevated 10- year risk of cervical precancer and cancer in women with human papillomavirus(HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice [J]. J Natl Cancer Inst,2005,97(14) :1072-1079.
4Kjaer SK,van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus(HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women:population based prospective follow up study[J]. BMJ, 2002,325 (7364) : 572.
5Wright TC Jr,Massad LS,Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnor- mal cervical cancer screening tests[J]. Am J Obstet Gynecot,2007,197(4) :346-355.
6Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined signifieance: baseline results from a randomized trial[J]. J Natl Cancer Inst, 2001,93 (4) :293-299.
7Arbyn M,Buntinx F,Van Ranst M,et al. Virologic versus cytologic triage of women with equivocal Pap smears: a recta-analysis of the accuracy to detect high-grade intraepithelial neoplasia[J]. J Natl Cancer Inst, 2004,96 (4) : 280- 293.
8Jordan J, Arbyn M, Martin-Hirsch P, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1 [J]. Cytopathology, 2008,19 (6) :342-354.
9李志刚（翻译）,Thomas C. Wright Jr,L Stewart Massad,Charles J. Dunton,MarkSpitzer,Edward J. Wilkinson,DianeSolomon.子宫颈癌筛查异常妇女处理的共识指南(2006版)[J].循证医学,2008,8(4):239-247. 被引量：16
10Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia[J]. Br J Cancer, 2001,84 (6) : 796- 801.
2zur Hausen H. Papillomaviruscs and cancer:from basic study to clinical application. Nat Rev Cancer, 2002, 2:342-350
3Bao Y P, Li N, Smith J S, et al. Human papillomavirus type-distribution in women from asia: A Meta-analysis. Int J Gynecol Cancer, 2007, 17:1-9
4Zhou J, Sun X Y, Stenzel D J, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial ceils is sufficient for assembly of HPV virion-like particles. Virology, 1991, 185:251-257
5Govan V A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther Clin Risk Manag, 2008, 4(1): 65-70
6Heymann W R. The human papillomavirus vaccine. J Am Acad Dermatol, 2008, 58(6): 1047- 1048
7Keam S J, Harper D M. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix], Drugs, 2008, 68(3): 359-372
1McMenamin M, McKenna M. Stability of human papillomavirus(HPV) in cervical ThinPrep specimens previously lysed with glacialacetic acid : effect on cobas 4800 HPV test performance [ J ]. CancerCytopathol,2014,122(4) :250-256.
2Diamantopoulou S, Spathis A, Chranioti A, et al. Liquid based cytolo-gy and HPV DNA testing in a Greek population compared to colposcopyand histology[ J]. Clin Exp Obstet Gynecol, 2013 ,40( 1) :131 - 136.
3Debeme M, Levy A, Mondini M, et al. The combination of the antiviralagent cidofovir and anti - EGFR antibody cetuximab exerts an antiprolif-.erative effect on HPV - positive cervical cancer cell lines'in - vitro andin - vivo xenografts. [ J]. Anticancer Drugs, 2013,24(6) :599 -608.
4Hosein F, Mohammed W, Zubach V,et al. Human papillomavirus gen-otypes in invasive cervical squamous cell carcinoma in Trinidad [ J].Rev Panam Salud Publica, 2013,33(4) :267 -270.
5Michimata R, Watari H, Tomaru U, et al. Human papillomavirus 16 -positive uterine cervical squamous cell carcinoma with coinfection withhuman papillomavirus 34 has a lower incidence in lymph node metastasisthan that without coinfection with human papillomavirus 34 [ J ]. Patho-biology, 2013,80(5) :259 -264.
6Huang Y,Lin M, Luo ZY,et al. Low prevalence of HPV in male sexu-al partners of HR - HPV infected females and low concordance of viraltypes in couples in Eastern Guangdong [ J ]. Asian Pac J Cancer Prev,2013,14(3) :1755 -1760.
7Indarti J, Aziz MF,Suiyawati B, et al. Scoring system and managementalgorithm assessing the role of survivin expression in predicting progres-sivity of HPV infections in precancerous cervical lesions[ J]. Asian PacJ Cancer Prev, 2013 ,14(3) :1643 - 1647.
8Castellsague X, Bosch FX, Munoz N. Environmental co- factors in HPV carcinogenesis[J]. Virus Res, 2002,89 (2) 191-199.
9Bosch FX,Manos MM,Munoz N,et al. Prevalence of hu- man papillomavirus in cervical cancer: a worldwide per spective[J]. J Nail Cancer Inst,1995,87(11):796 -802.
10Beby Defaux A,Bourgoin A,Ragot S,et al. Human papil- lomavirus infection of the cervix uteri in women attending a Health Examination Center of the French social security [J].J Med Virol,2004,73(2) ,262-268.
